Monitors safety of Fruzaqla in adults with metastatic colorectal cancer in South Korea
Observes side effects of Fruzaqla in adults with metastatic colorectal cancer.
Plain-language title generated from the registry record
Registry title: A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Yonsei University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT07035886
- Record updated
- 27 February 2026
- Original description
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.Read full original descriptionShow less
Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Inclusion: Age greater than or equal to (>=)18 years; Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea; Participant voluntarily consent to participate in the study.
Exclusion: Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label; Participants actively participating in other interventional clinical trial(s) on mCRC treatments; Pregnant or breastfeeding women.